In response, the FDA convened a training workshop at the Ghana Library Authority in Koforidua, where stakeholders involved in the handling of medicines and controlled substances were taken through updated regulatory requirements designed to preserve product integrity from source to patient. Officials said safeguarding the integrity of medicines throughout the supply chain was becoming increasingly critical as distribution networks expanded and regulatory risks evolved. 

Speaking on the sidelines of the training with the Ghana News Agency, Mr David Arhin, Principal Regulatory Officer of the FDA, said participants were being equipped with updated guidelines governing the supply, sale, and use of controlled substances to enhance compliance throughout the distribution chain. He explained that adherence to regulatory standards was essential to preventing misuse, diversion, and unauthorised access to controlled medicines, noting that weaknesses within distribution systems could undermine public confidence in healthcare delivery. 

Mr Arhin indicated that operators who failed to comply with established requirements risked sanctions under the country’s regulatory framework. “Compliance is not merely about satisfying regulatory requirements; it is about protecting lives,” he said. 

Participants were also taken through Good Storage and Distribution Practices requirements by Mr Kingsley N. Lamptey, Principal Regulatory Officer at the FDA, who stressed the importance of documentation, traceability, and maintaining appropriate storage conditions throughout the distribution process. He said distributors were expected to ensure proper storage conditions, maintain accurate documentation, guarantee product traceability, and institute systems capable of facilitating prompt product recalls where necessary. 

He noted that ineffective storage and distribution practices could expose medicines to conditions that reduce their potency, compromise treatment outcomes, and increase risks to patient safety. He stressed that compliance should not be regarded merely as a regulatory obligation but as a public health responsibility aimed at ensuring that medicines reaching consumers remained safe, effective, and of assured quality. 

Ms Anita Owusu-Kuffour, Eastern Regional Head of the FDA, urged participants to translate the knowledge acquired into everyday practice within their respective organisations. She said protecting the integrity of the pharmaceutical supply chain required collective commitment from regulators, distributors, wholesalers, and other stakeholders. 

Ms Owusu-Kuffour noted that continuous education and industry collaboration remained indispensable to addressing emerging regulatory challenges and strengthening consumer protection. The participants, drawn from institutions involved in the storage and distribution of pharmaceutical products, underwent pre- and post-training assessments and engaged in practical discussions on operational challenges confronting the sector. The training forms part of the FDA’s broader strategy to build regulatory capacity, improve compliance, and minimise vulnerabilities within Ghana’s medicine supply systems.